Omadacycline for Community-Acquired Bacterial Pneumonia

The New England Journal of Medicine
13 Feb, 2019 ,

In a double-blind trial, they randomly assigned adults with community-acquired bacterial pneumonia to receive omadacycline or moxifloxacin. Results suggest omadacycline was noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults.

Source